Illumina (NASDAQ:ILMN) Director Sells $35,088,591.96 in Stock

Posted by Brian Himes on Jun 4th, 2026

Illumina, Inc. (NASDAQ:ILMN – Get Free Report) Director Keith Meister sold 214,596 shares of the business’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $163.51, for a total value of $35,088,591.96. Following the completion of the sale, the director directly owned 3,065,452 shares in the company, valued at $501,232,056.52. This represents a 6.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Illumina Stock Up 5.2%

ILMN opened at $170.93 on Thursday. Illumina, Inc. has a one year low of $81.75 and a one year high of $172.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. The stock’s fifty day moving average is $136.19 and its 200-day moving average is $133.03. The company has a market capitalization of $25.86 billion, a PE ratio of 31.08, a P/E/G ratio of 2.69 and a beta of 1.50.

Illumina (NASDAQ:ILMN – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. During the same quarter in the previous year, the business earned $0.97 EPS. The company’s quarterly revenue was up 4.8% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. On average, equities analysts predict that Illumina, Inc. will post 5.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on ILMN. Barclays boosted their target price on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Guggenheim boosted their price objective on Illumina from $170.00 to $180.00 and gave the stock a “buy” rating in a report on Monday. Evercore reaffirmed an “outperform” rating on shares of Illumina in a research note on Friday, May 1st. Piper Sandler decreased their target price on shares of Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Finally, Daiwa Securities Group raised shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 target price on the stock in a research report on Thursday, May 14th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $138.38.

Get Our Latest Report on ILMN

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of ILMN. Elyxium Wealth LLC purchased a new stake in Illumina in the 4th quarter worth about $25,000. Board of the Pension Protection Fund acquired a new stake in Illumina during the 4th quarter worth about $26,000. Creative Capital Management Investments LLC grew its stake in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina during the 4th quarter valued at about $26,000. Finally, Laurel Wealth Advisors LLC acquired a new position in shares of Illumina in the 4th quarter valued at about $26,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Illumina

Here are the key news stories impacting Illumina this week:

Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and reiterated a Buy rating, reflecting optimism about clinical sequencing momentum, consumables pricing, and the company’s pipeline. Article
Positive Sentiment: Integrated DNA Technologies expanded its collaboration with Illumina, linking xGen FFPE and cfDNA workflows to DRAGEN and Connected Insights, which could deepen Illumina’s role in oncology research and support software adoption. Article
Positive Sentiment: Recent commentary highlighted Illumina’s better execution, stronger NovaSeq X adoption, and higher full-year 2026 guidance, which has helped extend the stock’s rally. Article
Neutral Sentiment: Illumina reported small insider sales, including a routine Rule 10b5-1 sale by the chief accounting officer, which is not unusual but adds to scrutiny around insider activity. SEC filing
Negative Sentiment: Director Keith A. Meister sold a large block of shares in multiple transactions, which could weigh on sentiment despite no direct sign of operational weakness. SEC filing

Illumina Company Profile

(Get Free Report)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.